#United States #Cambridge #Immunotherapy #Marengo Therapeutics #Invikafusp

Introduction

Marengo Therapeutics, Inc., a biotechnology company focused on developing innovative immunotherapeutic strategies, is set to present groundbreaking findings at the European Society of Medical Oncology (ESMO) Annual Meeting 2025. The presentation will highlight initial Phase 2 clinical data concerning invikafusp alfa, a first-in-class bispecific antibody designed to combat solid tumors that are resilient to immune checkpoint blockade.

Presentation Overview

The late-breaking presentation scheduled for October 17, 2025, will be part of a mini oral session focused on investigational immunotherapy. Dr. Antione Italiano from Institut Bergonié in France will lead the session, sharing pivotal findings from the STARt-001 trial. This trial focuses on the safety and efficacy of invikafusp alfa in treating patients with antigen-rich solid tumors, specifically those that have developed resistance to traditional therapies.

Details of the Presentation

• - Title: STARt-001 Initial Phase 2 Clinical Activity of Invikafusp Alfa
• - Abstract Number: LBA55
• - Session Time: October 17, 2025, from 14:00 to 15:30
• - Location: Nuremberg Auditorium, ESMO Annual Meeting 2025, Berlin, Germany

The Importance of Invikafusp

Invikafusp is a novel therapeutic agent that targets specific T cell receptor (TCR) subtypes found in solid tumors. This targeted approach aims not only to enhance immune response but also to foster long-lasting protection against cancer recurrence. The mechanism behind invikafusp involves a unique non-clonal method of TCR activation, which can significantly expand a diverse range of effector memory T cells, key players in the body’s immune defense.

STAR Platform and Clinical Trials

Marengo’s proprietary STAR™ platform has been instrumental in the development of invikafusp. This platform encompasses a library of antibodies targeted at germline-encoded variable regions of the TCR, combined with various T cell co-stimulation elements. Such a combination offers a sophisticated method to activate T cells, promoting effective anti-tumor responses.

The STARt-001 study is particularly compelling as it showcases the potential of this innovative treatment across a range of solid tumor types that are typically challenging to treat. With a global reach, this Phase 1/2 clinical trial has been designed to evaluate the safety, tolerability, and preliminary efficacy of invikafusp in biomarker-selected patients, specifically those with advanced disease who have failed prior therapies.

Looking Towards the Future

As Marengo Therapeutics prepares for its presentation at ESMO 2025, the anticipation builds around the potential implications of its findings for the future of cancer treatment. The results from the STARt-001 trial could lead to new treatment paradigms for managing tumors resistant to current standard therapies. Such advancements not only represent a significant leap in medical science but also offer hope to patients facing daunting challenges in their cancer battles.

For more information about the ongoing efforts and innovations at Marengo Therapeutics, interested parties should visit their website or review their latest updates through clinical trial registries.

Conclusion

The forthcoming presentation at ESMO 2025 is more than just a scientific milestone; it is a testament to the dedication and ingenuity of Marengo Therapeutics in the field of immunotherapy. As researchers continue to uncover the complexities of tumor resistance, treatments like invikafusp may pave the way for new standards in oncological care. Stay tuned for updates as they unfold in October 2025.